Wegovy recommended for approval for the treatment of obesity by CHMP

12 November 2021
novo_nordisk_copenhagen_large

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending marketing authorization for Wegovy (once-weekly semaglutide 2.4mg injection), from Danish diabetes care giant Novo Nordisk (NOV: N), chronic weight management in adults with obesity.

Wegovy is intended for chronic weight management in adults living with obesity (initial BMI≥30 kg/m2) or overweight (initial BMI≥27 kg/m2) with at least one weight-related comorbidity such as high blood pressure, heart disease or type 2 diabetes.

The positive CHMP opinion is based on results from the STEP Phase IIIa clinical trial program. Across the trials in people with obesity or overweight without type 2 diabetes, an average weight loss of 17-18% sustained over 68 weeks was reported for those treated with Wegovy. Wegovy demonstrated a safe and well-tolerated profile across the program, with the most common adverse events being gastrointestinal.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical